Compared to ICI blockers, the enhanced anti-tumour response would be achieved without instigating serious autoimmune side effects since pre-clinical studies in mouse models of autoimmune disease (i.e., EAE, CIA, and EAU) show that UMCD6 and other anti-CD6 mAbs reduce clinical signs of disease, pathogenic CD4+ Th1/Th17 responses, and inflammatory cell infiltration into the target organs [30,32,56,66]. This evidence concerns the gene CD6 and neoplasm.